# Serine control of retinal neovascularization in retinopathy

> **NIH NIH R01** · BOSTON CHILDREN'S HOSPITAL · 2024 · $442,500

## Abstract

Retinopathy of prematurity (ROP), a leading cause of blindness in children, afflicts ~14,000 premature infants
yearly in the US. About 1,500 of those develop severe ROP, requiring treatment. ROP has increased in the last
decade due to (1) increased multiple (and more preterm) births after in vitro fertilization; (2) increased
survival at low gestational ages at high ROP risk; and (3) higher levels of supplemental oxygen with more ROP
incidence. Current treatments (laser photocoagulation and anti-vascular endothelial growth factor (VEGF)
drugs) target late-phase retinal neovascularization and have adverse effects. We need to find new ways to treat
ROP. Nutrient deficiency occurs in preterm infants and is associated with ROP development. Early full amino
acid supplementation, starting the first day of life, improves weight gain, which in turn reduces ROP risk.
However, specific amino acid requirements are unknown. Circulating L-serine levels are lower in premature
infants with lower gestational age and higher risk for ROP. We preliminarily found that L-serine
supplementation prevents retinal neovascularization in a mouse model of ROP, and retinal glia might be the
primary retinal cells in response to L-serine. Therefore, we propose that:
L-serine affects retinal neovascularization by controlling glial cell angiogenic factors.
In the mouse model of ROP, we will examine if (1) L-serine supplements inhibits retinal neovascularization; (2)
retinal glial cells (which control neovascularization) mediate L-serine inhibitory effect on OIR; and (3) L-serine
decreases OIR by regulating glial pro-angiogenic factors via lactate.
This study will determine (1) if oral or i.p. L-serine inhibits neovascularization in OIR, modeling ROP and (2)
the role of glial cell L-serine synthesis and key mechanistic pathways in controlling pathologic retinal vessel
growth. Successful completion of our study will likely establish a critical role of L-serine in ROP prevention.
There is high translational value in this work, as oral or i.v. delivery of L-serine to preterm
infants is very feasible. Systemic L-serine supplementation may prevent ROP and might possibly prevent
other complications of preterm birth (intraventricular hemorrhage or bronchopulmonary dysplasia).

## Key facts

- **NIH application ID:** 10808186
- **Project number:** 5R01EY032492-04
- **Recipient organization:** BOSTON CHILDREN'S HOSPITAL
- **Principal Investigator:** Zhongjie Fu
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $442,500
- **Award type:** 5
- **Project period:** 2021-05-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10808186

## Citation

> US National Institutes of Health, RePORTER application 10808186, Serine control of retinal neovascularization in retinopathy (5R01EY032492-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10808186. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*